Why the study?
Metabolic syndrome increases cardiovascular disease risk primarily via arterial stiffness, but the role and mechanisms of PPM1B deubiquitination in high-fat/high-sucrose diet-induced arterial stiffness remained unclear.
ABRO1/BRCC3-mediated PPM1B deubiquitination promotes HFHSD-induced arterial stiffness, highlighting a potential therapeutic target for metabolic syndrome-related vascular disease.
Answers are grounded in this paper and cite their sources.
Should not change clinical practice; leaves open PPM1B pathway as hypothesis-generating target for metabolic vascular disease.
BACKGROUND: Metabolic syndrome heightens cardiovascular disease risk primarily through increased arterial stiffness. We previously demonstrated the involvement of YAP (Yes-associated protein) in high-fat/high-sucrose diet (HFHSD)–induced arterial stiffness via modulation of PPM1B (protein phosphatase Mg 2+ /Mn 2+ –dependent 1B)-lysine 63(K63) deubiquitination. In this study, we aimed to elucidate the role and mechanisms underlying PPM1B deubiquitination in HFHSD-induced arterial stiffness. METHODS: Enzymes governing PPM1B deubiquitination were identified through small interfering RNA (siRNA) screening and mass spectrometry. Glutathione S-transferase pull-down, coimmunoprecipitation, protein purification, and immunofluorescence were used to explore the mechanism underlying PPM1B deubiquitination. Doppler ultrasound was used to evaluate HFHSD-induced arterial stiffness in mice, and telemetry was used to record pulsatile (systolic and diastolic) blood pressure. RESULTS: Smooth muscle cell–specific PPM1B overexpression attenuated HFHSD-induced arterial stiffness in mice in a PPM1B-K326-K63–linked polyubiquitination-dependent manner. Mechanistically, ABRO1 (Abraxas brother 1; a core BRCC36 [BRCA1/BRCA2 (breast cancer type 1/2)–containing complex subunit 36] isopeptidase complex component) directly bound YAP and underwent liquid-liquid phase separation with YAP and PPM1B in a YAP-dependent manner, which in turn promoted PPM1B deubiquitination. Furthermore, smooth muscle cell–specific Abro1 -knockout mice and Brcc3 -knockout mice showed attenuated HFHSD-induced arterial stiffness and activation of transforming growth factor-β–Smad (mothers against decapentaplegic homolog) signaling. CONCLUSIONS: We elucidated the PPM1B deubiquitination mechanisms and highlighted a potential therapeutic target for metabolic syndrome–related arterial stiffness.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: